Aktis Oncology (NASDAQ:AKTS) Stock Price Expected to Rise, HC Wainwright Analyst Says

Aktis Oncology (NASDAQ:AKTS) had its price target hoisted by HC Wainwright from $30.00 to $33.00 in a research note issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the technology company’s stock. HC Wainwright’s price objective would suggest a potential upside of 93.32% from the company’s current price. HC Wainwright also issued estimates for Aktis Oncology’s Q1 2027 earnings at ($0.54) EPS, Q2 2027 earnings at ($0.57) EPS, Q3 2027 earnings at ($0.60) EPS and Q4 2027 earnings at ($0.63) EPS.

AKTS has been the subject of several other reports. Bank of America assumed coverage on Aktis Oncology in a research note on Tuesday, February 3rd. They issued a “buy” rating and a $34.00 price objective for the company. Wall Street Zen raised shares of Aktis Oncology to a “hold” rating in a report on Saturday, January 17th. Leerink Partners assumed coverage on shares of Aktis Oncology in a research report on Tuesday, February 3rd. They issued an “outperform” rating and a $31.00 target price for the company. JPMorgan Chase & Co. initiated coverage on shares of Aktis Oncology in a research note on Tuesday, February 3rd. They issued an “overweight” rating and a $30.00 price target on the stock. Finally, TD Cowen began coverage on shares of Aktis Oncology in a research report on Tuesday, February 3rd. They set a “buy” rating on the stock. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $32.00.

Aktis Oncology Stock Down 4.6%

Shares of Aktis Oncology stock opened at $17.07 on Tuesday. The firm’s 50 day moving average price is $19.13. Aktis Oncology has a 12 month low of $14.72 and a 12 month high of $29.16.

Insider Transactions at Aktis Oncology

In other news, major shareholder Bioventures 2018 L.P. Mpm acquired 1,112,777 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $20,029,986.00. Following the completion of the transaction, the insider owned 10,260,064 shares in the company, valued at approximately $184,681,152. This trade represents a 12.17% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Ansbert Gadicke bought 1,112,777 shares of the firm’s stock in a transaction on Monday, January 12th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $20,029,986.00. Following the completion of the acquisition, the insider directly owned 10,260,064 shares in the company, valued at $184,681,152. The trade was a 12.17% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 6,117,776 shares of company stock valued at $110,119,968 in the last three months. 3.30% of the stock is currently owned by corporate insiders.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.